| Literature DB >> 34595465 |
Reena V Jayani1,2, Joseph Pidala1, Heather Jim3, Junmin Whiting4, Qianxing Mo4, Asmita Mishra1.
Abstract
BACKGROUND: Physical function prior to allogeneic hematopoietic cell transplant (HCT) is associated with survival and may be associated with patient physical activity (PA). Tools to evaluate PA prior to HCT are scarce. We aimed to evaluate the impact of easily obtained patient-report of PA prior to HCT on survival.Entities:
Keywords: Allogeneic hematopoietic cell transplant; physical activity; stem cell transplantation
Year: 2021 PMID: 34595465 PMCID: PMC8432326 DOI: 10.2991/chi.k.210221.001
Source DB: PubMed Journal: Clin Hematol Int ISSN: 2590-0048
Figure 1CONSORT diagram.
Patient characteristics
|
|
|
| ||
|---|---|---|---|---|
|
| ||||
|
|
|
| ||
| Age (Median, range) | 57.85 (19.91–76.07) | 59.67 (20.3, 75.4) | 56.1 (22.3, 72.4) | 55.74 (19.9, 76.1) |
| Gender | ||||
| Female | 261 (44.5%) | 173 (51.3%) | 22 (42.3%) | 66 (33.3%) |
| Male | 326 (55.5%) | 164 (48.7%) | 30 (57.7%) | 132 (66.7%) |
| KPS | ||||
| 90–100 | 461 (78.5%) | 261 (77.4%) | 42 (80.8%) | 158 (79.8%) |
| ≤80 | 126 (21.5%) | 76 (22.6%) | 10 (19.2%) | 40 (20.2%) |
| HCT-CI | ||||
| Low | 98 (16.8%) | 44 (13.1%) | 10 (19.6%) | 44 (22.2%) |
| Intermediate | 166 (28.4%) | 84 (25.1%) | 17 (33.3%) | 65 (32.8%) |
| High | 320 (54.8%) | 207 (61.8%) | 24 (47.1%) | 89 (44.9%) |
| Number of prior chemotherapy | ||||
| <2 | 150 (26.8%) | 86 (27%) | 17 (32.7%) | 47 (24.9%) |
| ≥2 | 410 (73.2%) | 233 (73%) | 35 (67.3%) | 142 (75.1%) |
| Missing | 27 | |||
| Regimen intensity | ||||
| NMA | 269 (45.8%) | 165 (49%) | 32 (61.5%) | 84 (42.4%) |
| MAC | 318 (54.2%) | 172 (51%) | 20 (38.5%) | 114 (57.6%) |
| Disease Risk Index | ||||
| Low | 45 (8.0%) | 25 (7.8%) | 4 (8%) | 16 (8.5%) |
| Intermediate | 417 (74.3%) | 241 (74.8%) | 41 (82%) | 135 (71.4%) |
| High/very high | 99 (17.6%) | 56 (17.4%) | 5 (10%) | 38 (20.1%) |
| Primary disease | ||||
| Benign hematologic disorder | 17 (2.9%) | 10 (3%) | 0 (0%) | 7 (3.6%) |
| Lymphoid disorder | 139 (23.9%) | 71 (21.3%) | 9 (17.6%) | 59 (29.9%) |
| Myeloid disorder | 402 (69.2%) | 247 (74.2%) | 35 (68.6%) | 120 (60.9%) |
| Plasma cell disorder | 23 (4.0%) | 5 (1.5%) | 7 (13.7%) | 11 (5.6%) |
| FEV1 | ||||
| >80% | 467 (79.6%) | 268 (79.5%) | 40 (76.9%) | 159 (80.3%) |
| ≤80% | 120 (20.4%) | 69 (20.5%) | 12 (23.1%) | 39 (19.7%) |
| Acute GVHD | ||||
| 0–I | 297 (53.8%) | 170 (54.1%) | 25 (49%) | 102 (54.5%) |
| II–IV | 255 (46.2%) | 144 (45.9%) | 26 (51%) | 85 (45.5%) |
3 missing;
26 unable to be scored;
6 missing;
35 missing.
KPS, karnofsky performance status; NMA, nonmyeloablative; MAC, myeloablative; GVHD, graft-versus-host disease.
Univariate analysis of overall survival
|
|
|
|
|---|---|---|
| Physical activity | 0.94 (0.91–0.97) | <0.001 |
| Gender | ||
| Male | – | 0.437 |
| Female | 0.90 (0.69–1.18) | |
| KPS | ||
| ≤80% | 1.73 (1.28–2.34) | <0.001 |
| >80% | – | |
| HCT-CI | ||
| Low | – | <0.001 |
| Intermediate | 0.69 (0.44–1.07) | |
| High | 1.40 (0.97–2.04) | |
| Disease Risk Index | ||
| Low | – | <0.001 |
| Intermediate | 1.70 (0.99–2.93) | |
| High | 2.99 (1.66–5.38) | |
| FEV1 | ||
| ≤80% | 1.27 (0.93–1.73) | 0.134 |
| >80% | – | |
| Regimen intensity | ||
| MAC | 1.28 (0.98–1.67) | 0.074 |
| NMA | – | |
MAC, myeloablative conditioning; NMA, nonmyeloablative.
Overall survival multivariable analysis
|
|
|
|
|---|---|---|
| Physical activity | 0.954 (0.921–0.988) | 0.009 |
| HCT-CI | ||
| Low | – | 0.004 |
| Intermediate | 0.742 (0.472–1.165) | |
| High | 1.318 (0.904–1.921) | |
| Disease Risk Index | ||
| Low | – | <0.001 |
| Intermediate | 1.648 (0.94–2.887) | |
| High/very high | 2.758 (1.5–5.072) | |
Non-relapse mortality multivariable analysis
|
|
|
|
|---|---|---|
| Physical activity | 0.931 (0.891–0.972) | 0.0013 |
| HCT-CI | ||
| Low | – | 0.0145 |
| Intermediate | 0.838 (0.455–1.543) | |
| High | 1.523 (0.902–2.572) | |